Search the Newsreel

Modine Manufacturing (MOD) Could Be 40% Undervalued On Strong Q1 Results And 2027 Guidance

Why Century Global Commodities Corp stock is skyrocketing today

Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones

Moderna's Q2 2026 earnings call focused on two main priorities: maintaining revenue growth while cutting costs and advancing late-stage pipeline programs. The company reported revenues of $145 million, exceeding estimates, and a GAAP loss of $1.97 per share, matching expectations. Moderna reiterated its target …

The flu shot finally gets an upgrade

Moderna's new mRNA flu vaccine has been approved by the FDA, representing a significant public health advancement. This mRNA vaccine is expected to offer better protection against the flu compared to traditional vaccines because it can be produced faster, better addressing the rapid mutation …

The mRNA technology behind Moderna’s Covid vaccine reaches the flu

The FDA has approved Moderna's mFlusiva, the first mRNA-based flu vaccine for adults 50 and older, similar to their Covid-19 vaccine. This new vaccine offers a faster manufacturing process for annual flu shot updates and aims to enhance protection for vulnerable populations, despite causing …

Modis Navnirman Q1 Results: Net profit rises 27% YoY to ₹861 lakh

InMode Ltd. (INMD) Stock Analysis: Evaluating Growth Potential in the Medical Device Sector

This article analyzes InMode Ltd. (INMD), an Israel-based medical device company specializing in minimally invasive aesthetic treatments. It evaluates the company's financial performance, stock indicators, and market position, noting its innovative technology and strong free cash flow despite stagnant revenue growth. The analysis concludes …

Modular Medical Inc (MODD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Modi's Navnirman consolidated net profit rises 26.36% in the June 2026 quarter

Royal Bank of Canada Has $17.05 Million Stock Holdings in Modine Manufacturing Company $MOD

Royal Bank of Canada reduced its stake in Modine Manufacturing Company by 8.9% in the first quarter, selling 7,674 shares but still holding 78,688 shares valued at $17.05 million. Despite some analysts lowering price targets, the company maintains a "Moderate Buy" consensus rating, and …

What Moderna is and how it built its mRNA vaccine platform

Moderna, founded in 2010, is a Cambridge-based biotechnology company that pioneered mRNA medicine, becoming a global pharmaceutical player through its widely distributed Covid-19 vaccine. Its core thesis is that mRNA technology can be quickly adapted to target a wide range of diseases, leading to …

Bronstein, Gewirtz & Grossman, LLC Encourages InMode Ltd. (INMD) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of InMode Ltd. (INMD) following a public letter from a shareholder, Steel Partners Holdings L.P. The letter alleges governance failures and suspicious stock purchases by InMode's CEO around significant corporate events, …

Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock

Moderna's mRNA-based flu vaccine, mFLUVISA, has received FDA approval for seasonal influenza prevention in adults 50-64 (traditional approval) and 65+ (accelerated approval). This approval follows an initial refusal-to-file letter from the FDA in February, which was later rescinded after industry criticism. The vaccine is …

Moderna, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MRNA) 2026-08-06

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth …

Modis Navnirman hosts Q1 FY27 earnings call on Aug 10

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

Moderna has received U.S. FDA approval for its influenza vaccine, mFLUSIVA (mRNA-1010), for use in adults 50 years and older. This marks Moderna's fifth approved product globally and fourth FDA-approved product, making it the first mRNA-based flu vaccine. The company anticipates mFLUSIVA will be …

Moderna secures FDA approval for its first mRNA influenza vaccine

Moderna has received FDA approval for mFLUSIVA, its first mRNA-based influenza vaccine, for adults aged 50 and over. This marks Moderna's fourth FDA-approved product and its fifth authorized product worldwide, with distribution expected to begin soon for the 2026-2027 respiratory virus season. The approval …

Modular Medical moves forward with Pivot insulin pump commercialization

Modular Medical Inc. announced plans to begin the first phase of commercializing its Pivot tubeless patch pump in October 2026 across five key U.S. markets. This strategic rollout, supported by partner Inizio, targets regions with high concentrations of diabetes prescribers and patients using multiple …

Earnings Flash (INMD) InMode Ltd. Reports Q2 Revenue $95.6M, Vs. FactSet Est of $93.1M

InMode Ltd. (INMD) announced its second-quarter revenue reached $95.6 million, surpassing FactSet's estimate of $93.1 million. This report highlights the company's financial performance relative to market expectations.

InMode (NASDAQ:INMD) Q2 Revenue Inline, EPS Beats; Shares Dip 2.5%

InMode (NASDAQ:INMD) reported Q2 2026 financial results with revenue of $95.6 million, which was in line with consensus estimates, and non-GAAP EPS of $0.35, beating expectations by approximately 3%. Despite the earnings beat and inline revenue, shares dipped 2.5% in pre-market trading, following a …

Modine Manufacturing Co (MOD) Shares Fall 3.5% -- GF Value Says Still Overvalued

Modine Manufacturing Co (MOD) shares dropped 3.5% to $194.61, which is 27.5% above its GF Value™ estimate of $152.69, indicating it is overvalued. Despite a strong GF Score™ of 85/100, driven by growth and momentum, the valuation and a P/E ratio significantly above its …

InMode (INMD) Stock Margin Compression Deepens As Profitability Fades

InMode (INMD) is facing significant margin compression, with its trailing net margin falling to 20.7% in Q2 2026, roughly half of what it was a year prior. Despite broadly flat revenue year-over-year at US$95.6 million, net income declined by 36% to US$17.1 million, leading …

FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Process

The FDA has approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. This marks the first mRNA flu shot to receive approval, following a challenging review process. The vaccine, which uses the same technology as Moderna's COVID-19 shots, is expected to …

Moderna’s mRNA Flu Shot Wins US Approval in FDA Turnaround

Moderna Inc. has received US regulatory approval for its mRNA-based flu vaccine. The vaccine is approved for adults aged 50 and over, with traditional approval for ages 50-64 and accelerated approval for those 65 and older. This marks a significant victory for Moderna, especially …

US FDA approves first mRNA flu shot from Moderna

The U.S. Food and Drug Administration has approved Moderna's mFlusiva, making it the first mRNA-based vaccine for seasonal flu. The shot is approved for individuals aged 50 and older, with a traditional approval for ages 50-64 and an accelerated approval for those 65 and …

InMode reports stable Q2 2026 revenue at $95.6M, with a 13% rise in consumables sales and $501M cash reserves.

InMode Ltd. announced its Q2 2026 financial results, reporting stable revenue at $95.6 million, consistent with Q2 2025. The company saw a 13% increase in consumables and service revenue, primarily driven by international sales, and maintained a strong cash position of $501.1 million despite …

InMode Ltd. (INMD) CEO holds 4,299,226 shares and extends proposal deadline

InMode Ltd.'s CEO, Moshe Mizrahy, beneficially owns 4,299,226 Ordinary Shares, representing 7.90% of the company's class, with sole voting and dispositive power. An amendment to his beneficial ownership report indicates that the expiration date for a proposal from M.N. Business Strategy has been extended …

Global Net Lease Reports Second Quarter 2026 Results

Global Net Lease, Inc. – Reports Q2'26 AFFO Per Share of $0.22;Raises Full-Year AFFO Per Share Guidance to $0.82 – $0.85 and Increases Gross Transaction Volume to $700 Million – $800 Million – Closed Plus Disposition Pipeline Totals $263 Million, with Office Sales Representing …

InMode Ltd. (NASDAQ: INMD) CFO awarded 14,000 RSUs and reports holdings

InMode Ltd.'s CFO, Moshe Itzkovich, was granted 14,000 restricted stock units (RSUs) on August 4, 2026, as reported in a recent Form 4 filing. This award increases his direct holdings to 38,430 securities, which include newly granted RSUs, previously unvested RSUs, and ordinary shares. …

Moderna Appeals District Court Infringement Judgment over COVID Vaccines

Moderna has appealed a District Court judgment concerning patent infringement related to its COVID-19 vaccines, arguing that the U.S. government, not Moderna, should bear the liability under 28 U.S.C. § 1498(a). The company claims that its Spikemax® vaccine was developed and distributed "for the …

InMode (NASDAQ:INMD) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Moderna, Inc. SEC Filing (Aug 5, 2026)

This article reports on a Form 144 SEC filing by Moderna, Inc. (MRNA) on August 5, 2026. The filing indicates a proposed sale of 499,246 shares of common stock with an aggregate market value of $28,956,268.00, resulting from a stock option exercise by an …

Moderna Advances Ebola Vaccine Into Human Testing

Moderna has initiated a Phase 1 clinical trial for its investigational Ebola vaccine, mRNA-1469, which targets the Bundibugyo ebolavirus and has no currently licensed vaccines. This advancement follows a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), which committed up to $50 million. …

Modular Medical to Showcase Pivot at Diabetes Conference | MODD Stock News

Modular Medical (NASDAQ: MODD) will participate in the Association of Diabetes Care & Education Specialists 2026 Annual Conference from August 7-10, 2026, in Columbus, Ohio. The company will host booth #1516 to provide live demonstrations of its Pivot™ tubeless insulin patch pump, ahead of …

InMode Q2 2026 Earnings: Flat Revenue and Lower Margins

InMode (Nasdaq: INMD) reported flat Q2 2026 revenue of $95.6 million, matching the prior year, but GAAP diluted EPS dropped significantly to $0.29 from $0.42. The company experienced a decline in profitability due to higher product costs, increased operating expenses, and an unfavorable mix, …

InMode earnings beat by $0.02, revenue topped estimates

InMode (NASDAQ: INMD) reported second-quarter earnings per share of $0.35, surpassing analyst estimates by $0.02. The company's revenue for the quarter reached $95.6 million, exceeding the consensus estimate of $92.64 million. InMode's stock has seen a 10.10% increase in the last three months and …